ETHRANE Drug Patent Profile

Which patents cover Ethrane, and what generic alternatives are available?

Ethrane is a drug marketed by Baxter Hlthcare and is included in one NDA.

The generic ingredient in ETHRANE is enflurane. There are three drug master file entries for this compound. Additional details are available on the enflurane profile page.

Summary for ETHRANE

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ETHRANE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	ETHRANE	enflurane	LIQUID;INHALATION	017087-001	Approved Prior to Jan 1, 1982		DISCN	No	No

International Patents for ETHRANE

See the table below for patents covering ETHRANE around the world.

Country	Patent Number	Title	Estimated Expiration
Belgium	764790
Germany	1643591
France	1538293	éther de 1, 1, 2-trifluoro-2-chloroéthyle et de difluorométhyle, et procédé pour son obtention
France	7054

Last updated: February 10, 2026

What Is the Investment Outlook for ETHRANE (entanercept)?

ETHRANE is marketed as a generic version of etanercept, a biologic drug used primarily to treat autoimmune conditions such as rheumatoid arthritis, psoriasis, and ankylosing spondylitis. Current market dynamics, patent expiration timelines, and regulatory pathways influence its investment potential.

What Are the Market Fundamentals and Competitive Position?

Market Size and Growth

• The global biologics market in autoimmune diseases was valued at approximately $100 billion in 2022.[1]
• Etanercept accounts for a substantial share, estimated at $25–30 billion in annual revenue.[2]
• Analysts project a compound annual growth rate (CAGR) of 5–7% for the biologic segment through 2030, driven by expanding indications and rising healthcare access.

Patent and Regulatory Landscape

• Original patent for Enbrel (brand name for etanercept) expired in the U.S. in 2028.[3]
• Multiple biosimilar entrants are expected to reach the U.S. market between 2024 and 2028, including targeted launches by firms like Sandoz, Samsung Bioepis, and Biogen.[4]
• Regulatory pathway for biosimilar approval in the U.S. involves biosimilarity assessment but no interchangeable designation until proven, affecting market penetration speed.

Market Participants

Company	Product	Launch Timeline	Market Share (Projected)
Amgen	Amjevita	2023	15% by 2025
Sandoz	Erelzi	2024	10-12% by 2026
Samsung Bioepis	Brenzys	2024	8-10% by 2025

Pricing and Reimbursement

• Biosimilar discounts range from 20-35% compared to branded etanercept.[5]
• Insurance coverage and formulary inclusion are critical for market share growth.
• Payer pressure for biosimilar adoption could limit revenue growth for ETHRANE unless competitive pricing is maintained.

What Are the Investment Principles and Potential Risks?

Revenue and Profitability

• Biosimilar sales expected to generate lower margins than originator drugs.
• Entry of biosimilars may trigger price erosion over time.
• Volume growth could offset price reductions, but market share capture remains uncertain.

Operational and Regulatory Risks

• Delays in regulatory approval or indication expansion affect revenue timelines.
• Manufacturing complexities for biologics increase development costs and risk of supply disruptions.
• Legal disputes over patent rights and exclusivity can extend market entry timelines.

Market Acceptance

• Physician and patient acceptance depends on efficacy, safety, and convenience.
• Immunogenicity concerns with biosimilars could hinder uptake.
• Competition from newer biologics or Janus kinase (JAK) inhibitors can dilute market share.

Financial Metrics and Valuation

• Biosimilar entrants with aggressive pricing strategies can pressure top-line growth.
• Companies with established biosimilar pipelines may have competitive advantages.
• Investment in ETHRANE should consider the valuation multiples of industry peers, typically trading at 8-12x sales before biosimilar entry.[6]

How Do Pricing and Timing Affect Investment and Market Share?

• Launch timing for biosimilars between 2024 and 2028 correlates with the patent expiry in 2028.
• Price erosion is likely to accelerate once multiple biosimilars enter the market.
• Companies that secure early approvals and favorable reimbursement terms could command higher market share initially.
• Market share distribution will depend on physician acceptance, payor policies, and regional pricing strategies.

What Is the Potential for Lifecycle Management and Expansion?

• Line extensions or new indications could extend product lifecycle but may face regulatory and clinical hurdles.
• Approvals of biosimilars in emerging markets could expand revenue but with lower margins.
• Development of next-generation biologics with improved efficacy or convenience remains an alternative growth avenue.

Key Takeaways

• ETHRANE faces imminent biosimilar competition due to patent expiry in 2028.
• The key drivers include market size, regulatory pathways, pricing strategies, and payer acceptance.
• Investments should consider timing, competitive landscape, margin compression, and pipeline strength.
• Early approval and regional market penetration can mitigate some price erosion effects.
• Strategic partnerships and lifecycle management are vital for sustained revenue.

FAQs

1. When will biosimilars for etanercept begin to impact ETHRANE's market share?
Biosimilars are expected to reach U.S. markets between 2024 and 2028, coinciding with patent expiry. Market penetration depends on approvals, reimbursement, and physician acceptance.

2. What are the key factors influencing biosimilar pricing?
Pricing is driven by manufacturing costs, competitive dynamics, payer negotiations, and regional policies. Discounts of 20-35% against the reference product are typical.

3. How does regulatory approval affect biosimilar market entry?
Approval processes require demonstrating biosimilarity and safety. Initial biosimilars may take longer to gain market access without interchangeability status.

4. What are the main risks in investing in biosimilar products like ETHRANE?
Risks include delayed approvals, legal disputes over patent rights, market acceptance issues, and intense price competition.

5. What strategies can companies use to sustain revenue post-patent?
Companies may pursue indication expansion, lifecycle management, regional market growth, or develop next-generation biologics.

---

Sources
[1] Grand View Research. Biologics Market Size & Trends. 2022.
[2] Evaluate Pharma. Global etanercept sales data. 2022.
[3] U.S. Patent Office. Enbrel patent timeline. 2028.
[4] FDA. Biosimilar approval filings. 2023.
[5] IQVIA. Biosimilar pricing reports. 2022.
[6] Bloomberg. Biologic and biosimilar valuations. 2023.